Skip to main content

Table 1 Main features of all included studies used in the diagnostic meta-analysis

From: Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis

Author and reference Year Region Cancer type/cases Patients TNM (I/II/III/IV) Control type/number Test matrix Method Cut-off Setting Sensitivity Specificity AUC QUADAS score
Wang et al. [21] 2014 China EC/286 48/107/94/37 HC/250 Serum ELISA 1000 pg/mL 0.381 0.968 0.897 11
Fisher et al. [22] 2015 Australia EC/40 14/15/8/1 Non-cancer/98 Tissue MT-PCR 961 pg/mL 0.88 0.64 0.86 10
EC/30 11/10/8/1 Non-cancer/69 Plasma ELISA 811 pg/mL 0.83 0.62 0.70
Blanco-Calvo et al. [15] 2014 Spain GC/52 9(I-II)/12/31 HC/23 Serum ELISA > 325.28 ng/mL 0.7308 0.913 0.8796 10
GC/52 9(I-II)/12/31 HC/23 Serum ELISA > 294.4 ng/mL 0.8889 0.8261 0.884
Wang et al. [16] 2014 China PC/807 45/127/337/298 Pancreatitis & benign tumors/165 Serum ELISA 1000 pg/mL 0.658 0.967 0.739 11
PC/172 stage I-II: 172 HC/500 Serum ELISA 1000 pg/mL 0.651 0.95 /
Koopmann et al. [17] 2006 Australia PC/50 3/5/39/3 HC/50 Serum ELISA 1583 pg/mL 0.9 0.84 0.99 10
PC/50 3/5/39/3 Pancreatitis/50 Serum ELISA 1583 pg/mL 0.9 0.44 0.81
Kaur et al. [18] 2013 America PC/91 5/37/2/38/9(missing) HC/24 Plasma ELISA > 2.3 ng/mL 0.62 0.63 0.85 10
PC/91 5/37/2/38/9(missing) Pancreatitis/23 Plasma ELISA > 2.3 ng/mL 0.62 0.78 0.74
PC/42 Stage I-II: 42 HC/24 Plasma ELISA > 2.2 ng/mL 0.81 0.64 0.85
PC/49 Stage III-IV: 49 HC/24 Plasma ELISA > 1. 6 ng/mL 0.78 0.58 0.94
PC/42 Stage I-II: 42 Pancreatitis/23 Plasma ELISA > 2.3 ng/mL 0.76 0.78 0.85
PC/49 Stage III-IV: 49 Pancreatitis/23 Plasma ELISA > 3.5 ng/mL 0.55 0.91 /
Koopmann et al. [19] 2004 Australia PC/80 1/3/58/10/8(missing) Non-cancer/216 Serum ELISA 1070 pg/mL 0.71 0.78 0.81 10
Xue et al. [12] 2010 China CRC/144 Stage I-II: 68
Stage III-IV: 76
HC/156 Serum ELISA 1144 pg/mL 0.778 0.994 0.897 11
Wang et al. [13] 2017 China CRC/473 51/153/201/68 HC/489 Serum ELISA 1000 pg/mL 0.438 0.967 0.866 10
Shen et al. [24] 2018 China Liver cancer/92 18/24/31/19 Benign liver disease: 53
HC: 40
Serum ELISA 1573.23 ng/L 0.8123 0.8399 / 10
Hogendorf et al. [20] 2018 Poland PC/42 3/16/9/14 Pancreatitis/21 Serum ELISA 2.7 ng/mL 0.738 0.7619 / 10
Liu et al. [23] 2015 China HCC/223 Unclear Hepatitis/88 Serum ELISA 2.463 ng/mL 0.631 0.8661 0.7882 11
HCC/223 Unclear Non-cancer/290 Serum ELISA 1.945 ng/mL 0.8679 0.7275 0.8426
  1. Abbreviations: MT-PCR multiplexed tandem PCR, QUADAS Quality Assessment for Studies of Diagnostic Accuracy, EC esophageal carcinoma, CRC colorectal cancer, HC healthy control, GC gastrointestinal cancer, PC pancreatic cancer, HCC hepatocellular carcinoma, AUC area under the curve, ELISA enzyme linked immunosorbent assay